Phaseline

Companies › Neuren Pharmaceuticals

Neuren Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NNZ-2591
NMDA receptor modulator (N-methyl-D-aspartate receptor GluN2B subunit modulator)
GRIN2BPhase 3Phelan-McDermid SyndromeOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07281079NNZ-2591Phase 3Phelan-McDermid SyndromeOtherOct 2027
NCT07593391NNZ-2591Phase 3Phelan-McDermid SyndromeOtherOct 2028

Targets

GRIN2B (1)

Companies with the same targets

Praxis Precision Medicines Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx BnH Research Johnson & Johnson (Janssen) SyneuRx International (Taiwan)

Companies built like this

GRIN Therapeutics Syndeio Biosciences Huons Biopharma Tetra Discovery Partners Prove pharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.